Aclaris Therapeutics, INC Form 4 insider transactions

Aclaris Therapeutics, Inc. Director William D. Humphries has reported the acquisition of common stock and new derivative securities, including stock options and restricted stock units, as part of his compensation.

Aclaris Therapeutics, Inc. Director Maxine Gowen reported the acquisition of stock options and restricted stock units, alongside the vesting of previously granted RSUs, as part of the company's non-employee director compensation policy.

Aclaris Therapeutics, Inc. Director Christopher P. Molineaux reported the acquisition of 4,793 common shares through RSU vesting and new grants of 42,350 stock options and 11,580 restricted stock units.

Jesse Wayne Hall, Chief Medical Officer of Aclaris Therapeutics, was granted stock options and restricted stock units on May 1, 2025, according to a Form 4 filing.

CEO Neal Walker of Aclaris Therapeutics reports acquisition and disposal of common stock related to restricted stock units.

CEO Neal Walker reports acquisition and disposal of Aclaris Therapeutics stock related to restricted stock units.

Kevin Balthaser, CFO of Aclaris Therapeutics, reports the vesting and subsequent transactions of restricted stock units.

CEO Neal Walker reports acquisition and disposal of Aclaris Therapeutics stock related to restricted stock units and tax obligations.

Joseph Monahan, Chief Scientific Officer of Aclaris Therapeutics, reports exercising restricted stock units and disposing of shares to cover tax obligations on March 1, 2025.

Hugh M. Davis, President and COO of Aclaris Therapeutics, reports acquisition of stock options and restricted stock units.

Interim CEO of Aclaris Therapeutics, Neal Walker, reports acquisition and disposal of common stock and restricted stock units.

Joseph Monahan, Chief Scientific Officer of Aclaris Therapeutics, reports the vesting and tax withholding of restricted stock units, as well as the grant of new restricted stock units and stock options.

Kevin Balthaser, CFO of Aclaris Therapeutics, reports the acquisition and disposal of company stock and derivative securities, including restricted stock units and stock options, in a recent Form 4 filing.

James Loerop, Chief Business Officer of Aclaris Therapeutics, reports the vesting and tax withholding of restricted stock units and the grant of new restricted stock units and stock options.

Aclaris Therapeutics' Chief Scientific Officer, Joseph Monahan, reported the acquisition and disposal of company stock and restricted stock units.

Aclaris Therapeutics' Chief Financial Officer, Kevin Balthaser, reported multiple transactions involving the acquisition and disposal of company stock and restricted stock units.

Aclaris Therapeutics' Chief Business Officer, James Loerop, reported the acquisition and disposal of company stock and restricted stock units, including transactions to cover tax obligations.

Aclaris Therapeutics' Interim CEO, Neal Walker, reported the acquisition and disposal of company stock and restricted stock units.

Aclaris Therapeutics' Chief Scientific Officer, Joseph Monahan, reported the disposition of 15,000 shares of common stock on December 10, 2024.

Aclaris Therapeutics' Interim CEO, Neal Walker, exercised stock options and sold shares to cover the exercise price and tax obligations.

Aclaris Therapeutics' President and COO, Hugh M. Davis, received stock options and restricted stock units as part of an inducement plan.

Aclaris Therapeutics' Interim CEO, Neal Walker, reported the acquisition of 9,466 shares of common stock through the vesting of restricted stock units and the disposal of 2,721 shares to cover tax obligations.

Aclaris Therapeutics director, Anand Mehra, acquired 666,666 shares of common stock at $2.25 per share on November 19, 2024.

Interim CEO of Aclaris Therapeutics, Neal Walker, reports acquisition and disposal of common stock and restricted stock units.

Interim CEO of Aclaris Therapeutics, Neal Walker, reports acquisition and disposal of common stock and restricted stock units on October 1, 2024.

Kevin Balthaser, CFO of Aclaris Therapeutics, reports the vesting and settlement of restricted stock units and associated tax withholding.

Neal Walker, Interim President and CEO of Aclaris Therapeutics, reports the vesting of restricted stock units and subsequent tax withholding of shares.

Interim CEO of Aclaris Therapeutics, Neal Walker, exercises stock options and acquires 43,548 shares of common stock at $0.72 per share on August 9, 2024.

Interim CEO of Aclaris Therapeutics, Neal Walker, reports acquisition and disposal of common stock related to restricted stock units.

Braden Michael Leonard, a director and potential 10% owner of Aclaris Therapeutics, has increased his indirect holdings through BML Investment Partners, L.P. by purchasing additional shares of common stock.